✦ LIBER ✦

Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen–Positive Chronic Hepatitis B Patients

✍ Scribed by Wong, Grace Lai–Hung; Wong, Vincent Wai–Sun; Choi, Paul Cheung–Lung; Chan, Anthony Wing–Hung; Chim, Angel Mei–Ling; Yiu, Karen Ka–Lam; Chan, Hoi–Yun; Chan, Francis Ka–Leung; Sung, Joseph Jao–Yao; Chan, Henry Lik–Yuen

Book ID: 121956783
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 628 KB
Volume: 7
Category: Article
ISSN: 1542-3565
DOI: 10.1016/j.cgh.2008.10.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

350 CLINICAL FACTORS PREDICTING ADVANCED

350 CLINICAL FACTORS PREDICTING ADVANCED LIVER FIBROSIS IN HEPATITIS B E ANTIGEN POSITIVE CHRONIC HEPATITIS B

✍ H.L. Chan; G.L. Wong; P.C. Choi; A.W. Chan; A.M. Chim; K.K. Yiu; H.Y. Chan; V.W. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Comparison of hepatitis B surface antige

Comparison of hepatitis B surface antigen and e antigen in predicting liver histology in hepatitis B e antigen-positive chronic hepatitis B patients

✍ Wang, Hong; Yan, Rong; Zhou, Yin; Wang, Ming Shan; Ruo, Guo Qin; Cheng, Mei Juan 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 502 KB

Viral factors correlate with hepatitis B

Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B

✍ Chun-Jen Liu; Pei-Jer Chen; Ming-Yang Lai; Feng-Yi Lin; Tzusan Wang; Jia-Horng K 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

Characterization of viral kinetics in pa

Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B

✍ I-Chin Wu; Nan-Haw Chow; Pin-Nan Cheng; Wen-Chun Liu; Kung-Chia Young; Wei-Lun C 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract A study was conducted during a 1 year follow‐up to characterize the viral kinetics in hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B and to develop a model of predicting the probability of spontaneous HBeAg seroconversion. Fifty‐seven patients with HBeAg‐positive chronic hep

Efficacy of lamivudine in patients with

Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Factors That Predict Response of Patient

Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa

✍ Erik H.C.J. Buster; Bettina E. Hansen; George K.K. Lau; Teerha Piratvisuth; Stef 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 1003 KB